Clinical Potential of Prefusion RSV F-specific Antibodies

• Autores: Iebe Rossey, Jason S. McLellan, Xavier Saelens, Bart Scherens
• Localización: Trends in microbiology, ISSN 0966-842X, Vol. 26, Nº. 3, 2018, págs. 209-219
• Idioma: inglés
• Enlaces
  • Texto Completo Ejemplar
• Resumen

  • Human respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in the very young. The RSV fusion protein (F) is essential for virus entry because it mediates viral and host membrane fusion. During this fusion process F is converted from a metastable prefusion conformation into an energetically favored postfusion state. Antibodies that target F can prevent viral entry and reduce disease caused by RSV. During recent years, many prefusion F-specific antibodies have been described. These antibodies typically have stronger RSV-neutralizing activity compared to those that also bind F in the postfusion conformation. Here, we describe how F-specific antibodies protect against RSV and why specifically targeting prefusion F could have great clinical potential.